About Assembly Biosciences
Assembly Biosciences is a company based in New York (United States) founded in 2005. Assembly Biosciences has raised $700 thousand across 3 funding rounds from investors including Gilead and Armistice Capital. The company has 73 employees. Assembly Biosciences offers products and services including ABI-5366 and Herpesvirus Programs. Assembly Biosciences operates in a competitive market with competitors including Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
- Headquarter New York, United States
- Employees 73
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website assemblybio.com
- Social LinkedIn
- Legal Name Assembly Biosciences, Inc.
- Annual Revenue$72.3 M (USD)153.52as on Dec 31, 2025
- Net Profit-$6.12 M (USD)84.76as on Dec 31, 2025
- EBITDA-$11.99 M (USD)73.53as on Dec 31, 2025
- Total Equity Funding$700K (USD)
in 3 rounds
- Latest Funding Round$20.1M (USD), Post-IPO
Dec 2024
- InvestorsGilead
& 1 more
- Employee Count73
Products & Services of Assembly Biosciences
Assembly Biosciences offers a comprehensive portfolio of products and services, including ABI-5366 and Herpesvirus Programs.
Long-acting candidate for treating herpes simplex virus infections.
Innovative treatments for recurrent genital herpes and transplant-associated viruses.
Funding Insights of Assembly Biosciences
Assembly Biosciences has successfully raised a total of $700K across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20.1 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $700,000
- Total Rounds 3
- Last Round Post-IPO — $20.1M
- First Round $700,000
(May 2010)
- Investors Count 2
All 3 funding rounds of Assembly Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $20.1M | Post-IPO | – | – | |
| Jun 2024 | – | Post-IPO | – | – | |
| May 2010 | $700,000 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Assembly Biosciences
Assembly Biosciences has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Gilead and Armistice Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | gilead.com | Foster City, United States | |
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States |
Investor details for Assembly Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Assembly Biosciences
57 people are tracked at Assembly Biosciences (36 in leadership, 15 in board & advisors, 6 in team); the tracked headcount is 73.
| Name | Role | Group |
|---|---|---|
Hassan Pajouhesh | Senior Director Medicinal Chemistry | Leadership |
Qi Huang | Vice President, Virology Discovery | Leadership |
Eimi Heebner | Associate Director, Program Management | Leadership |
Kimmy Liu | Director | Leadership |
Yogesh Naik | Director Informatics | Leadership |
Tom Pratt | Executive Director IT | Leadership |
Kelly Louie | Associate Director, Analytical Development & QC | Leadership |
Yanhong Zhu | Senior Director Of Toxicology | Leadership |
Mark Johnson | Associate Director | Leadership |
Katie Zomorodi | Executive Director, Clinical Pharmacology | Leadership |
Suzette DeVito | Executive Assistant TO THE Chief Executive Officer | Leadership |
Katie Kitrinos | Senior Vice President, Preclinical Research and Development | Leadership |
Marc P. Windisch | Director Discovery Biology | Leadership |
Min Zhong | Executive Director, Medicinal Chemistry | Leadership |
Kirsten Stray | Associate Scientific Director | Leadership |
Robb Anderson | Executive Director, Human Resources, Organizational Development | Leadership |
Christine Day | Associate Director, Human Resources | Leadership |
Grace Wang | Vice President Clinical Development | Leadership |
John O. Gunderson | VP, General Counsel and Corporate Secretary | Leadership |
Jian Zhang | Sr. Director, Medicinal Chemistry | Leadership |
37 more people are available in the full profile.
Complete people profiles for Assembly Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Assembly Biosciences
Assembly Biosciences is a publicly listed company on the NASDAQ with ticker symbol ASMB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Dec 2010
- Listed onNASDAQ: ASMB
- Listed entityAssembly Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS0453962070
- Share price$23.53 (+3.11% on the day) · 2026-10-09
- Market capitalisation$479.1M
- EPS (diluted, trailing year)$-0.07
- Volume (last session)170,489
Financials of Assembly Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $72.3M | -$6.1M | -$12.0M |
| 2024 | $28.5M | -$40.2M | -$45.3M |
| 2023 | $7.2M | -$61.2M | -$64.2M |
| 2022 | – | -$93.1M | -$92.5M |
| 2021 | $6.2M | -$129.8M | -$91.9M |
Detailed financial statements for Assembly Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Assembly Biosciences
4 dated milestones of Assembly Biosciences across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Assembly Biosciences is founded.
- Funding First funding round of $700K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.1M.
Competitors of Assembly Biosciences
Assembly Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biological E, Vir Biotechnology, Vaxcyte, Cidara Therapeutics and Freeline, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| ardelyx.com | 2007 | Fremont, United States | $61.1M | 37 | Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases |
Detailed competitors of Assembly Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Assembly Biosciences
The website of Assembly Biosciences (assemblybio.com) receives about 5.8K visits a month and ranks #3,402,677 among all websites worldwide, #4,451 in Biotechnology and Pharmaceuticals.
- Monthly visits5.8K
▲ 17.8% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,402,677
among all websites
- Category rank#4,451
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.3
- Average visit52 sec
- DevicesDesktop 54% · Mobile 46%
Websites whose visitors overlap most with Assembly Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellasgenetherapies.com | 100% | 1K | – | View details | |
| mbcbiolabs.com | 99% | – | #2,013,343 | View details | |
| allogene.com | 98% | 33.5K | #1,405,171 | View details | |
| aligos.com | 98% | 3.4K | #3,982,602 | View details | |
| corvuspharma.com | 97% | 13.6K | #3,366,661 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Assembly Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Assembly Biosciences
Complete news archive for Assembly Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Assembly Biosciences
10 companies that operate in the same segment as Assembly Biosciences (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Assembly Biosciences
Assembly Biosciences was founded in 2005 and raised its 1st funding round 5 years after it was founded.
Assembly Biosciences is headquartered in New York, United States. It is registered at New York, New York, United States.
Assembly Biosciences is a funded company, having raised a total of $700K across 3 funding rounds to date. The company's 1st funding round was a Seed of $700K, raised on May 2010.
Assembly Biosciences has 73 employees.
Annual revenue of Assembly Biosciences is $72.3M as on Dec 31, 2025.
Assembly Biosciences was founded in 2005 through a merger of Ventrus Biosciences and Assembly Pharmaceuticals. Operations are centered in the biotechnology sector, with a focus on infectious diseases and gastrointestinal disorders. Small molecule agents targeting the HBV core protein are being advanced, alongside microbiotic therapies utilizing the Gemicel platform for targeted GI delivery of live biotherapeutics. The company is based in New York, United States.
Assembly Biosciences's top competitors include Vaxcyte, Serum Institute of India and Ardelyx.
Assembly Biosciences offers ABI-5366 and Herpesvirus Programs.
Yes, Assembly Biosciences is publicly traded on NASDAQ under the ticker symbol ASMB.
Assembly Biosciences has 2 investors. Key investors include Gilead, and Armistice Capital.
Assembly Biosciences operates through Assembly Biosciences, Inc..